09/08/2022
Finally, the long-lasting, peptide-powered frown line treatment your patients have been wanting is now approved! DAXXIFY™ (daxibotulinumtoxinA-lanm) injection is the first and only peptide-powered, FDA-approved frown line treatment with a median duration of 6 months and up to 9 months for some patients.*
Experience the future of aesthetics with –coming soon for exclusive providers. Visit https://bit.ly/3xo6mQv to learn more about partnering with us.
Tap the share icon to spread the news about DAXXIFY™–the only long-lasting, peptide-powered frown line treatment.
Watch for Important Safety Information. For Full Prescribing Information, including Boxed Warning and Medication Guide, see https://bit.ly/3QqQxPm.
DAXXIFY™ is a prescription medicine for adults to temporarily improve the look of moderate to severe frown lines between the eyebrows. Ask your doctor to tell you about DAXXIFY™. DAXXIFY™ may cause serious side effects hours to weeks after injection. Alert your doctor right away as difficulty swallowing, speaking, breathing, eye problems or muscle weakness can be a sign of a life-threatening condition. The most common side effects are headache, eyelid drooping, and loss of the ability to move some muscles in your face.
Call your doctor for medical advice about side effects. Intended for US audiences.
*At least 50% of patients in SAKURA 1 and SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and 23.9 weeks (6 months) or longer, respectively, per both investigator's and patient's assessments. 5% of patients in SAKURA 1 and 3% of patients in SAKURA 2 had none or mild frown lines at 9 months per investigator’s assessment. In SAKURA 1, SAKURA 2, and SAKURA 3 OLS Treatments 1 and 2, 7.5%, 5.4%, 17.4%, and 11.6% of patients, respectively, had not returned to baseline severity at 9 months per both investigator’s and patient’s assessments.
